Berdahl, John P. http://orcid.org/0000-0002-5468-7405
Sarkisian, Steven R. Jr http://orcid.org/0000-0001-7633-2720
Ang, Robert E. http://orcid.org/0000-0002-5035-2923
Doan, Long V. http://orcid.org/0009-0008-0572-2236
Kothe, Angela C. http://orcid.org/0009-0000-7971-5292
Usner, Dale W. http://orcid.org/0000-0002-2799-0652
Katz, L. Jay
Navratil, Tomas http://orcid.org/0009-0007-3577-3096
Ang, Robert E. T.
Bacharach, Jason
Bagga, Harmohina
Bashford, Kent P.
Berdahl, John P.
Chu, Yun-Sen Ralph
Cionni, Robert J.
Crane, Charles J.
D’Ambrosio, Francis A.
ElMallah, Mohammed K.
Goyal, Raj K.
Jones, Jason J.
Kim, Joshua W.
Lehmann, Robert P.
Lin, Christopher
Lubeck, David M.
Marquis, Robert E.
McCabe, Cathleen M.
Reiss, George R.
Sarkisian, Steven R. Jr.
Sorenson, Robert C.
Tyson, Farrell C. II
Vold, Steven D.
Weber, Charles H.
Wu, Bin
Yomtoob, David E.
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension
https://doi.org/10.1007/s40265-023-01973-7
Article History
Accepted: 5 November 2023
First Online: 7 December 2023
Declarations
:
: This study was sponsored by Glaukos Corporation (Aliso Viejo, CA). Glaukos participated in the design of the study, data management, analysis and interpretation, and the preparation, review, and approval of the manuscript.
: John P. Berdahl has received consulting fees, paid advisory board member or received fees for attending a meeting for AbbVie, Aerpio, Alcon, Aldeyra, Aurea Medical, Aurion Biotech/CorneaGen, Balance Ophthalmics, Bausch and Lomb, Dakota Lions Eye Bank, Elios Vision Inc., Equinox, Expert Opinion, Glaukos, Gore, Imprimis, Interfeen, iRenix, Iacta Pharmaceuticals, IVERIC bio, Inc., JNJ, Kala, Kedalion, MELT Pharmaceuticals, MicroOptx, New World Medical, Ocular Surgical Data, Ocular Therapeutix, Omega Ophthalmic, Orasis, Oyster Point, RxSight, Santen, Sight Sciences, Surface Inc., Tarsus, Tear Clear, Vertex Ventures, ViaLase, Vittamed, Vance Thompson Vision, Versea Biologics, Visionary Ventures, Visus and Zeiss; has received lecture fees (honoraria), travel fees or reimbursements when speaking for AbbVie, Alcon and Glaukos; has equity ownership/stock options of Aurion Biotech/CorneaGen, Balance Ophthalmics, Equinox, Expert Opinion, Interfeen, Ocular Surgical Data, Omega Ophthalmic, Surface Inc, Vance Thompson Vision, Verana Health and Zeiss; owns stock of Glaukos; has patents and/or royalties with Imprimis. Steven R. Sarkisian Jr is a consultant/advisor for Alcon, Allergan, Bausch + Lomb, Beaver-Visitec International, Glaukos, Icare USA, Katena Products, MicroSurgical Technology, Ocular Science, Santen, and Sight Sciences; is on the speaker’s bureau for Alcon, Allergan, and Bausch + Lomb; has received grant support from Alcon, Allergan, Allysta Pharmaceuticals, Elios, Glaukos, iSTAR Medical, Ocular Science, Ocular Therapeutix, and Sight Sciences; and holds stock or stock options in Ocular Science and Sight Sciences. Robert E. Ang has been a speaker for, and received research support from Glaukos. Long V. Doan, L. Jay Katz, Angela C. Kothe, Dale W. Usner and Tomas Navratil are employees of Glaukos Corporation and may hold Glaukos stock/stock options.
: Institutional review board or independent ethics committee approval was obtained at each site before the study began, and the study was performed in compliance with good clinical practice, the principles of the Declaration of Helsinki, or the laws and regulations of the country in which the study was conducted (ClinicalTrials.gov registration number NCT02754596).
: All patients in this study provided written informed consent before undergoing any study-related procedure.
: The datasets generated during and/or analyzed during the current study are not publicly available due to ongoing US Food and Drug Administration review of a New Drug Application for the travoprost intraocular implant but are available from the corresponding author on reasonable request.
: Not applicable
: Study design: LVD, LJK; data collection: JPB, SRS, REA; statistical analysis: DWU; data interpretation: JPB, SRS, REA, LVD, LJK, ACK, DWU, TN; authoring, revisions, and approval of the manuscript: JPB, SRS, REA, LVD, LJK, ACK, DWU, TN.